30 completed, 8 recruiting, 6 active not recruiting, 5 terminated. 56 Phase 1, 16 Phase 2.
Follow Abdominal Neoplasms: new trials by email Literature Review of Abdominal Neoplasms trials Research Report on Abdominal Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TLR9 Immunotherapy for Peritoneal Carcinomatosis ACM-CpG - Malignant Ascites, Colorectal Adenocarcinoma | Phase 1 | Recruiting | Brown University | 24 | 2026-08-25 | 2026-10-01 |
| Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors Mitomycin C (MMC), Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) - Peritoneal Carcinomatosis | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 24 | 2026-08-05 | 2026-09-16 |
| Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer Pressurized intraperitoneal aerosol chemotherapy (PIPAC) using paclitaxel - Ovarian Neoplasms, Peritoneal Neoplasms | Phase 1 / Phase 2 | Not yet recruiting | Seoul National University Hospital | 53 | 2026-01-01 | 2025-12-09 |
| Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis Paclitaxel, NALIRIFOX - Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 | Recruiting | University of Colorado, Denver | 10 | 2025-12-31 | 2026-02-02 |
| A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer or Malignant Peritoneal Mesothelioma M28z1XXPD1DNR CAR - Mesothelin Positive, Mesothelin-Expressing Tumors | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 32 | 2024-09-30 | 2026-10-15 |
| Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) and Electrostatic PIPAC (ePIPAC) With Paclitaxel In Patients With Peritoneal Carcinomatosis Paclitaxel - Peritoneal Carcinomatosis | Phase 1 | Unknown | National University Hospital, Singapore | 36 | 2023-08-04 | 2024-05-29 |
| Galunisertib Combined With Capecitabine in Advanced CRC With PM Galunisertib plus capecitabine - Colorectal Cancer Metastatic, Peritoneal Carcinomatosis | Phase 1 / Phase 2 | Active not recruiting | The Netherlands Cancer Institute | 31 | 2023-07-28 | 2026-07-13 |
| A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) - Advanced Solid Tumors, Genital Neoplasm, Female | Phase 1 / Phase 2 | Recruiting | Marengo Therapeutics, Inc. | 366 | 2023-01-04 | 2026-08-11 |
| AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer AB-1015 - Carcinoma, Ovarian Epithelial, Ovarian Neoplasms | Phase 1 | Active not recruiting | Arsenal Biosciences, Inc. | 19 | 2022-11-29 | 2026-09-03 |
| Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer PIPAC with Nal-IRI - Peritoneal Carcinomatosis, Peritoneal Metastases | Phase 1 | Active not recruiting | University Hospital, Ghent | 45 | 2022-11-21 | 2026-07-13 |
| Intraperitoneal Paclitaxel-loaded TPM for Treatment of Peritoneal Carcinomatosis Paclitaxel-loaded tumor penetrating microparticles - Peritoneal Carcinomatosis | Phase 1 | Terminated | Carlos Chan | 4 | 2022-04-26 | 2026-02-25 |
| A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors Felmetatug Vedotin, Pembrolizumab - Ovarian Neoplasms, Peritoneal Neoplasms | Phase 1 | Terminated | Seagen, a wholly owned subsidiary of Pfizer | 250 | 2022-01-12 | 2026-01-09 |
| Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies Sodium Thiosulfate, 5-Fluorouracil, Oxaliplatin - Peritoneal Mesothelioma, Peritoneal Carcinomatosis | Phase 1 | Recruiting | National Cancer Institute (NCI) | 60 | 2021-10-19 | 2026-10-16 |
| Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer Combined PIPAC / IV chemotherapy treatment - Metastatic Ovarian Carcinoma, Peritoneal Carcinomatosis | Phase 1 | Recruiting | Hospices Civils de Lyon | 15 | 2021-07-30 | 2026-10-06 |
| PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis Nab paclitaxel, Cisplatin - Peritoneal Carcinomatosis | Phase 1 | Unknown | University Hospital, Geneva | 18 | 2020-11-11 | 2024-05-24 |
| Intraperitoneal Docetaxel in Combination With mFOLFOX6 for Gastric Cancer Patients With Peritoneal Carcinomatosis Intraperitoneal docetaxel - Peritoneal Carcinomatosis | Phase 1 | Terminated | Johns Hopkins University | 2 | 2020-11-01 | 2024-08-09 |
| PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer Biopsy, Cisplatin, Doxorubicin - Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8 | Phase 1 | Recruiting | City of Hope Medical Center | 49 | 2020-08-21 | 2026-08-26 |
| Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis Radspherin - Peritoneal Carcinomatosis, Ovarian Cancer | Phase 1 | Completed | Oncoinvent Solutions AS | 21 | 2020-06-08 | 2026-04-17 |
| Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer Paclitaxel - Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 27 | 2019-12-06 | 2026-10-06 |
| A Phase I Study Evaluating SCB-313 for the Treatment of Subjects With Peritoneal Carcinomatosis SCB-313 - Peritoneal Carcinomatosis | Phase 1 | Terminated | Sichuan Clover Biopharmaceuticals, Inc. | 10 | 2019-09-10 | 2023-04-12 |
Showing 20 of 56. Sign in to see all of them.
Peritoneal Neoplasms (53) · Ovarian Neoplasms (26) · Fallopian Tube Neoplasms (14) · Stomach Neoplasms (13) · Colorectal Neoplasms (11) · Neoplasms (6) · Pancreatic Neoplasms (6) · Appendiceal Neoplasms (5) · Carcinoma, Ovarian Epithelial (5) · Gastrointestinal Neoplasms (5) · Breast Neoplasms (4) · Carcinoma (4) · Neoplasm Metastasis (4) · Carcinoma, Non-Small-Cell Lung (3)
Neoplasms by Site (55) · Digestive System Diseases (54) · Digestive System Neoplasms (53) · Peritoneal Diseases (52) · Neoplasms (50) · Endocrine System Diseases (30) · Endocrine Gland Neoplasms (29) · Female Urogenital Diseases (28) · Female Urogenital Diseases and Pregnancy Complications (28) · Genital Diseases (28) · Genital Diseases, Female (28) · Urogenital Diseases (28) · Adnexal Diseases (27) · Gonadal Disorders (27)
Cisplatin (8) · Oxaliplatin (6) · Paclitaxel (5) · Albumin-Bound Paclitaxel (4) · Carboplatin (4) · Doxorubicin (4) · Fluorouracil (4) · 130-nm albumin-bound paclitaxel (3) · Mitomycin (3) · Taxes (3) · Cytoreduction Surgical Procedures (2) · Docetaxel (2) · Hyperthermic Intraperitoneal Chemotherapy (2) · Irinotecan (2) · Leucovorin (2)
M.D. Anderson Cancer Center (5) · National Cancer Institute (NCI) (5) · Celgene (2) · City of Hope Medical Center (2) · Hospices Civils de Lyon (2) · National University Hospital, Singapore (2) · University Hospital, Ghent (2) · AGO Study Group (1) · Arsenal Biosciences, Inc. (1) · AstraZeneca (1) · Boehringer Ingelheim (1) · Brown University (1) · Carlos Chan (1) · CritiTech, Inc. (1) · Dan Blazer III, M.D. (1)
United States (33) · Belgium (5) · Spain (5) · France (4) · Germany (4) · Canada (3) · Netherlands (3) · China (2) · Norway (2) · Singapore (2) · South Korea (2) · Australia (1) · Italy (1) · Japan (1) · Switzerland (1)
Andrea Hayes-Jordan, MD (2) · Wim P Ceelen, MD, PhD, Prof (2) · Alexis Leal, MD (1) · Amir A Jazaeri (1) · Andrew M Blakely, M.D. (1) · Arsenal Biosciences (1) · Bok Yan Jimmy So, MBChB (1) · Bradley Switzer, MD (1) · Brian D Badgwell (1) · Carlos Chan, MD, PhD (1) · Charles Levenback, MD (1) · Dan Blazer, MD (1) · David L Bartlett, MD (1)
PMID 21424369, PMID 27742126, PMID 29773661, PMID 30623229, PMID 30911663, PMID 33037105, PMID 34070561, PMID 34206826, PMID 35551444, PMID 35843174, PMID 36604127, PMID 37227734, PMID 37489066, PMID 38471508, PMID 38702618, PMID 39288528, PMID 41349345, PMID 42383154
2018 (2), 2023 (2), P01CA132714 (1), P30CA006973 (1), P30CA033572 (1), U01CA070095 (1), U01CA132123 (1), UM1CA186644 (1), UM1CA186691 (1)